<DOC>
	<DOC>NCT00102128</DOC>
	<brief_summary>Study to examine the safety and effectiveness of implanted skeletal muscle cells (cells removed from the thigh muscle) into scarred areas of heart muscle after heart attack.</brief_summary>
	<brief_title>Study to Examine the Safety and Effectiveness of Implanted Skeletal Muscle Cells (Cells Removed From the Thigh Muscle) Into Scarred Areas of Heart Muscle After Heart Attack.</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<criteria>Patients recommended for coronary bypass surgery (preferably with cardiopulmonary support) Ejection fraction ≥15% and ≤35% Left ventricular myocardial infarction (MI heart attack) ≥4 weeks prior to screening Need for a rapid surgical coronary revascularization Need for any other related cardiosurgical measure during coronary surgery (e.g. mitral valve repair or valve replacement) Patients with a left ventricular aneurysm who is a candidate for left ventricular aneurysmectomy or left ventricular reduction surgery; patient receiving left or biventricular (BiV) pacing therapy for heart failure (unless the patient has stabilized after 6 or more months of this therapy) Cardiomyopathy presumed to be of nonischemic origin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>